PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
Moraes Ribeiro E., Secker K.A., Nitulescu A.M., Schairer R., Keppeler H., Wesle A., Schmid H., Schmitt A., Neuber B., Chmiest D. et al., 2024/01/31. Journal for immunotherapy of cancer, 12 (1) pp. e007829. Peer-reviewed.
ici le détail